Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
6(75.0%)
Phase 2
2(25.0%)
8Total
Phase 1(6)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT07243340Phase 1Not Yet Recruiting

A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor

Role: lead

NCT04370587Phase 1Recruiting

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Role: lead

NCT06971614Phase 2Recruiting

A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

Role: lead

NCT04780217Phase 1Active Not Recruiting

Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

Role: lead

NCT05756556Phase 2Suspended

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

Role: lead

NCT05602792Phase 1Unknown

A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors

Role: lead

NCT05598268Phase 1Unknown

A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.

Role: lead

NCT05095441Phase 1Not Yet Recruiting

A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma

Role: lead

All 8 trials loaded